Gratus Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$243K Buy
3,539
+294
+9% +$19.6K 0.01% 327
2024
Q1
$238K Buy
+3,245
New +$250K 0.01% 292
2021
Q2
Sell
-4,181
Closed -$270K 186
2021
Q1
$270K Sell
4,181
-120,603
-97% -$7.78M 0.03% 163
2020
Q4
$7.27M Buy
+124,784
New +$7.53M 0.97% 48
2020
Q1
Sell
-104,053
Closed -$6.76M 192
2019
Q4
$6.76M Buy
104,053
+1,473
+1% +$95.9K 1.03% 38
2019
Q3
$6.5M Buy
+102,580
New +$6.71M 1.06% 35
2017
Q4
Sell
-2,683
Closed -$217K 183
2017
Q3
$217K Buy
+2,683
New +$205K 0.03% 171
2016
Q3
Sell
-64,044
Closed -$5.34M 177
2016
Q2
$5.34M Sell
64,044
-2,508
-4% -$223K 0.79% 34
2016
Q1
$6.11M Sell
66,552
-8,247
-11% -$744K 1.34% 27
2015
Q4
$7.57M Buy
74,799
+10,941
+17% +$1.14M 1.72% 6
2015
Q3
$6.27M Buy
63,858
+45,113
+241% +$5.01M 1.51% 6
2015
Q2
$2.19M Sell
18,745
-6,470
-26% -$707K 0.51% 52
2015
Q1
$2.47M Sell
25,215
-95
-0.4% -$9.65K 0.55% 46
2014
Q4
$2.39M Buy
+25,310
New +$2.62M 0.56% 39

Other funds holding GILD

Gratus Capital's GILD Position: Q2 2024 in Review

Gratus Capital increased its Gilead Sciences (GILD) stake by 9.1% in Q2 2024, buying an estimated $19.6K and bringing the position to 3,539 shares worth $243K. The position accounts for 0.01% of the portfolio, ranked #327.

Gratus Capital first reported a position in GILD in Q4 2014 and has held it in 14 quarters since. The position peaked at $7.57M in Q4 2015. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.

  • Gratus Capital held 3,539 shares of Gilead Sciences worth $243K as of Q2 2024.
  • Gratus Capital bought 294 Gilead Sciences shares in Q2 2024, an estimated $19.6K.
  • Gilead Sciences made up 0.01% of Gratus Capital's portfolio in Q2 2024, its #327 holding.
  • Gratus Capital first reported a position in Gilead Sciences in Q4 2014 and has held it in 14 quarters since.
  • Gratus Capital's Gilead Sciences position peaked at $7.57M in Q4 2015.
  • 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.